

Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.



Sectoral Healthcare Opportunities Fund

ISIN: LU1849505026, share class: PH, currency: EUR
a sub-fund of Variopartner SICAV

This fund is managed by Vontobel Asset Management S.A., which is part of Vontobel Group.

This fund is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

Objectives and investment policy

This actively managed sub-fund aims to generate long-term capital growth in USD. It is categorized as Article 8 SFDR. More details can be found in the prospectus.

- The sub-fund invests mainly in equities and equity-like transferable securities. It may invest up to 33% via Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect in China A-Shares. The sub-fund is allowed to invest up to 10% in Special Purpose Acquisition Companies (SPAC). It may also hold cash up to 20% of its net assets.
- The sub-fund invests globally in the health-care sectors of pharmaceuticals, biotechnology, medical devices and health-care services. The investment manager integrates environmental, social and governance (ESG) factors into the investment process in order to identify, monitor and mitigate ESG risks and opportunities. For further details please refer to the sales prospectus. In order to achieve this objective, the Sub-Fund invests, while respecting the principle of risk diversification, primarily in equities (including, but not limited to, common stocks, preferred stocks, or other securities convertible into

common stock) equity-like transferable securities, participation certificates etc. of small, mid and large cap issuers, located worldwide, in the following healthcare sectors: Healthcare Equipment and Services, Pharmaceuticals, Biotechnology & Lifesciences.

- The sub-fund may use derivatives to achieve the investment objective and for hedging purposes (including currency hedging).
- The currency of this class is continually hedged against the sub-fund's main currency. This hedging does not necessarily cover all currency risks. It entails costs which in turn reduce the share class' return.
- The sub-fund is not managed with reference to a benchmark. The portfolio manager has full investment discretion within the predefined investment limits.
- Any income generated will be reinvested and included in the value of your shares.
- Buying and selling securities entails transaction costs payable in addition to the charges listed.
- Redemption of shares: daily when banks in Luxembourg are open for normal business (see prospectus for details and exceptions).

Risk and reward profile



The indicator above does not signal the risk of a potential loss, but indicates the fluctuations in the sub-fund's share price in the past.

- The share class is assigned to this category because its share price can fluctuate sharply due to the investment policy applied.
- The historical data used to calculate the profile cannot be used as a reliable guide to the future risk profile of the sub-fund.
- The risk category shown is not guaranteed and may change.
- Even the lowest risk category is not entirely free of risk.

When assigning a sub-fund's share class to a risk category, it may be the case that not all risks are taken into account due to the calculation model

used. Such risks include risks in connection with exceptional market events, operational errors, legal and political events. You can find a detailed list of the risks in the "Notice regarding general risks" section of the General Part and the "Risk profile" section of the Special Part of the sales prospectus.

The following risks have no direct influence on this category, but may still be important:

- The portfolio has lower risk diversification as the focus lies on companies within a specific investment theme.
- Using derivatives generally creates leverage and entails valuation risks and operational risks. Leverage magnifies gains but also losses. Over-the-counter derivatives involve corresponding counterparty risks.
- The investment manager applies ESG criteria in its investment process which may affect the sub-fund's investment performance positively or negatively since the execution of the ESG strategy may result in foregoing opportunities to buy certain securities, and/or selling securities due to their ESG-related characteristics.
- Investments in China A-Shares are subject to changes in political, economic and social conditions in China as well as changes in the policies of the PRC government, laws and regulations.

Charges

The charges you pay are used to pay the costs of running the fund, including the costs for managing, marketing and distributing it. These charges reduce the return on your investment.

One-off charges taken before or after you invest	
Entry charge	2.00%
Exit charge	0.00%
Conversion fee	1.50%
This is the maximum that might be taken out of your money before it is invested / before the proceeds of your investment are paid out.	
Charges taken from the fund over a year	
Ongoing charges	1.64%
Charges taken from the fund under certain specific conditions	
Performance fee	
Performance Fee is charged on the portfolio's excess return beyond 5 % p.a. - details to be found in the prospectus. 5.21% of the net asset value of the share class was paid out for the past financial year.	


The one-off charges shown are maximum figures. In some cases, you might pay less – you can find this out from your financial advisor.

The figure for ongoing charges is based on the past twelve months as at 30.06.2022. This figure may vary from year to year. It does not include:

- The fund's transaction costs except for those paid by the fund when buying or selling shares of other collective investment schemes.
- Performance fee

For more information on charges, please see the “Fees and expenses” section in the general and special parts of the sales prospectus at www.sectoral.com.

Past performance



The chart shows past performance based on full calendar years. One-off charges are not included when calculating performance.

- Past performance is not an indicator of current or future returns.
- The stated performance of the share class includes ongoing charges, but excludes one-off charges.
- Shares were first issued for this share class in 2007. Sub-fund launch year: 1993.
- The sub-fund uses the BM MSCI TR World Net Health Care USD Index for performance comparison only.
- Past performance of the fund is shown in the currency of the share class (EUR).
- **The class PHARMA/wHEALTH SICAV - Sub-fund One R (EUR H) was launched on May 2, 2007 and merged with the share class Variopartner SICAV - PHARMA/wHEALTH P H EUR on August 31, 2018. The performance before this date was therefore achieved under circumstances that no longer apply.**

Practical information

- The fund's depositary is RBC Investor Services Bank S.A.
- You can find the sales prospectus, up-to-date semi-annual and annual reports, share prices as well as other practical information on the fund in English and German free of charge at: www.sectoral.com.
- To obtain the documents, you can also contact Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg.
- The fund is subject to Luxembourg tax law. This may have an impact on your investment in the fund, depending on where you live. If you have any questions in this regard, please contact your tax advisor.
- Information re. the current remuneration policy, including a description of how remuneration and benefits are calculated and the identities of persons responsible for awarding the remuneration and benefits, is available at www.vontobel.com/AM/remuneration-policy.pdf and will be provided for free in hardcopy upon request.
- This sub-fund is part of an umbrella fund. The various sub-funds are not liable for one another, i.e. only the gains and losses of this sub-fund are relevant for you as a shareholder. You can request the conversion of some or all of your shares in the sub-fund in accordance with the rules set out in the sales prospectus.
- Vontobel Asset Management S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the fund.